

State of Oklahoma SoonerCare

Verzenio[®] (Abemaciclib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
) Start Date (or date of next dose): Dosing Regimen:	
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
For Initial Authorization (Initial approval will be for the duration of 6 months): 1. Please indicate diagnosis and information: Advanced or Metastatic Breast Cancer A. Is disease hormone receptor (HR)-positive? Yes No B. Is disease human epidermal growth factor receptor 2 (HER2)-negative? Yes No i. Will abemaciclib be used in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women? Yes No ii. Will abemaciclib be used in combination with fluvestrant with disease progression following endocrine therapy? Yes No		
Prescriber Signature:	is modically necessary and	Date:
Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.		

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 84 5/2/2023